Net loss attributable to common stockholders was $28.9 million, which consisted of a $5.3 million loss from discontinued operations, for 2021, or a basic and diluted loss per share attributable to common stockholders of $0.12. This is compared to a net loss attributable to common stockholders of $26.9 million, which consisted of a $0.1 million loss from discontinued operations, for the previous fiscal year, or a basic and diluted loss per share attributable to common stockholders of ($0.24).

• A Phase 2b smoking cessation study progressed, following a positive meeting with the FDA to review Mydecine's Investigational New Drug (IND) application.
• Mydecine agreed to supply MYCO-001 for Dr. Matthew Johnson's smoking cessation study, which is being carried out at Johns Hopkins University, New York University, and the University of Alabama Birmingham.
• The company signed a five-year Master Collaboration Research Agreement with Johns Hopkins University School of Medicine.
• New independent board members were added to the company, including Gordon Neal, Josephine Wu, Dr. Saeid Babaei, and Dr. Victoria Hale.